Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Increased expression of urokinase plasminogen activator (uPA) has been reported in various malignancies including prostate cancer. However, the mechanism by which uPA is abnormally expressed in prostate cancer remains elusive. Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples. This aberrant expression is associated with cancer-linked demethylation of the uPA promoter. Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo. Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

[1]  J. S. Rao,et al.  CpG island promoter methylation and silencing of 14-3-3σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2 , 2006, Oncogene.

[2]  C. Gondi,et al.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.

[3]  C. Gondi,et al.  Proteases and Glioma Angiogenesis , 2005, Brain pathology.

[4]  Wei Zhao,et al.  Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. , 2005, Cancer research.

[5]  R. Dahiya,et al.  Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer , 2005, Clinical Cancer Research.

[6]  Carmen Jerónimo,et al.  P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation , 2005, Clinical Cancer Research.

[7]  Joachim Diebold,et al.  Functional epigenomics identifies genes frequently silenced in prostate cancer. , 2005, Cancer research.

[8]  M. Szyf DNA Methylation and Demethylation as Targets for Anticancer Therapy , 2005, Biochemistry (Moscow).

[9]  Kazuhiko Aoyagi,et al.  Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. , 2005, Cancer research.

[10]  R. Dahiya,et al.  Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Shailesh Singh,et al.  Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion , 2004, Clinical Cancer Research.

[12]  D. McNeel,et al.  Newer therapies in advanced prostate cancer. , 2004, Clinical prostate cancer.

[13]  Achim Krüger,et al.  Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents*[boxs] , 2004, Journal of Biological Chemistry.

[14]  M. Szyf,et al.  Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis* , 2004, Journal of Biological Chemistry.

[15]  G. De Petro,et al.  Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. , 2004, Molecular cancer therapeutics.

[16]  S. Rabbani,et al.  Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma , 2004, Clinical Cancer Research.

[17]  Robert A Sikes,et al.  Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer , 2004, Reproductive biology and endocrinology : RB&E.

[18]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[19]  C. Gondi,et al.  Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis , 2003, Oncogene.

[20]  J. S. Rao,et al.  Molecular mechanisms of glioma invasiveness: the role of proteases , 2003, Nature Reviews Cancer.

[21]  M. Szyf,et al.  The Methyl Donor S-Adenosylmethionine Inhibits Active Demethylation of DNA , 2003, Journal of Biological Chemistry.

[22]  S. Rabbani,et al.  Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Aguirre-Ghiso,et al.  ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK , 2003 .

[25]  D. Dinh,et al.  Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. , 2003, International journal of oncology.

[26]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[27]  J. Aguirre-Ghiso,et al.  ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). , 2003, Cancer research.

[28]  P. Carmeliet,et al.  uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.

[29]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[30]  C. Legrand,et al.  uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. , 2001, Experimental cell research.

[31]  S. Mohanam,et al.  Regulation of the uPA gene in various grades of human glioma cells. , 2001, International journal of oncology.

[32]  C. Rinker-Schaeffer,et al.  Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.

[33]  P. Russell,et al.  Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.

[34]  A. V. von Eschenbach,et al.  External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. , 2000, International journal of radiation oncology, biology, physics.

[35]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[36]  J. Foekens,et al.  Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[37]  H. Miyake,et al.  Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. , 1999, International journal of oncology.

[38]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[39]  R. Sadasivan,et al.  Urokinase-type plasminogen activator expression in human prostate carcinomas. , 1996, The American journal of the medical sciences.

[40]  E. Hedley‐Whyte,et al.  Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.

[41]  P. Dettmar,et al.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.

[42]  J. Bruner,et al.  Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. , 1994, Cancer research.

[43]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[44]  Michael J. Wilson,et al.  Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior , 1991, The Prostate.

[45]  A. Mazar,et al.  Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. , 1991, Cancer communications.

[46]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.

[47]  G. Satta,et al.  Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine:S-adenosylhomocysteine ratio. , 1989, Carcinogenesis.

[48]  H. Keer,et al.  Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. , 1989, The Journal of urology.

[49]  B. Binder,et al.  Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. , 1988, The Journal of urology.

[50]  K. Danø,et al.  immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma , 1984, The Journal of cell biology.